Heparin	0	7	B-Drug_or_compound
-	7	8	O
steroid	8	15	B-Drug_or_compound
conjugates	16	26	O
:	26	27	O
new	28	31	O
angiogenesis	32	44	O
inhibitors	45	55	O
with	56	60	O
antitumor	61	70	B-Pathological_formation
activity	71	79	O
in	80	82	O
mice	83	87	B-Organism
.	87	88	O

Inhibitors	90	100	O
of	101	103	O
angiogenesis	104	116	O
hold	117	121	O
potential	122	131	O
in	132	134	O
the	135	138	O
treatment	139	148	O
of	149	151	O
cancer	152	158	B-Pathological_formation
and	159	162	O
other	163	168	O
diseases	169	177	O
where	178	183	O
the	184	187	O
disease	188	195	O
is	196	198	O
caused	199	205	O
or	206	208	O
maintained	209	219	O
by	220	222	O
the	223	226	O
inappropriate	227	240	O
growth	241	247	O
of	248	250	O
blood	251	256	B-Multi-tissue_structure
vessels	257	264	I-Multi-tissue_structure
.	264	265	O

In	266	268	O
the	269	272	O
present	273	280	O
study	281	286	O
,	286	287	O
a	288	289	O
novel	290	295	O
inhibitor	296	305	O
of	306	308	O
angiogenesis	309	321	O
was	322	325	O
synthesized	326	337	O
by	338	340	O
covalently	341	351	O
linking	352	359	O
a	360	361	O
nonanticoagulating	362	380	O
derivative	381	391	O
of	392	394	O
heparin	395	402	B-Drug_or_compound
,	402	403	O
heparin	404	411	B-Drug_or_compound
adipic	412	418	I-Drug_or_compound
hydrazide	419	428	I-Drug_or_compound
(	429	430	O
HAH	430	433	B-Drug_or_compound
)	433	434	O
,	434	435	O
by	436	438	O
an	439	441	O
acid	442	446	O
-	446	447	O
labile	447	453	O
bond	454	458	O
to	459	461	O
the	462	465	O
antiangiogenic	466	480	O
steroid	481	488	B-Drug_or_compound
,	488	489	O
cortisol	490	498	B-Drug_or_compound
.	498	499	O

The	500	503	O
rationale	504	513	O
was	514	517	O
that	518	522	O
the	523	526	O
heparin	527	534	B-Drug_or_compound
derivative	535	545	O
,	545	546	O
which	547	552	O
binds	553	558	O
to	559	561	O
sulfated	562	570	O
polyanion	571	580	O
receptors	581	590	O
on	591	593	O
endothelial	594	605	B-Cell
cells	606	611	I-Cell
,	611	612	O
should	613	619	O
concentrate	620	631	O
the	632	635	O
steroid	636	643	B-Drug_or_compound
on	644	646	O
the	647	650	O
surface	651	658	O
of	659	661	O
vascular	662	670	B-Cell
endothelial	671	682	I-Cell
cells	683	688	I-Cell
.	688	689	O

Endocytosis	690	701	O
of	702	704	O
the	705	708	O
conjugate	709	718	O
and	719	722	O
decomposition	723	736	O
of	737	739	O
the	740	743	O
acid	744	748	O
-	748	749	O
labile	749	755	O
linkage	756	763	O
inside	764	770	O
lysosomes	771	780	O
and	781	784	O
other	785	790	O
acidic	791	797	O
intracellular	798	811	O
compartments	812	824	O
should	825	831	O
then	832	836	O
lead	837	841	O
to	842	844	O
release	845	852	O
of	853	855	O
the	856	859	O
cortisol	860	868	B-Drug_or_compound
and	869	872	O
expression	873	883	O
of	884	886	O
its	887	890	O
antiproliferative	891	908	O
activity	909	917	O
.	917	918	O

Analysis	919	927	O
of	928	930	O
the	931	934	O
stability	935	944	O
of	945	947	O
HAH	948	951	B-Drug_or_compound
-	951	952	I-Drug_or_compound
cortisol	952	960	I-Drug_or_compound
showed	961	967	O
that	968	972	O
it	973	975	O
was	976	979	O
stable	980	986	O
at	987	989	O
pH	990	992	O
7	993	994	O
.	994	995	O
4	995	996	O
and	997	1000	O
broke	1001	1006	O
down	1007	1011	O
rapidly	1012	1019	O
(	1020	1021	O
t1	1021	1023	O
/	1023	1024	O
2	1024	1025	O
15	1026	1028	O
min	1029	1032	O
)	1032	1033	O
at	1034	1036	O
pH	1037	1039	O
4	1040	1041	O
.	1041	1042	O
8	1042	1043	O
at	1044	1046	O
37	1047	1049	O
degrees	1050	1057	O
C	1058	1059	O
.	1059	1060	O

Treatment	1061	1070	O
of	1071	1073	O
murine	1074	1080	B-Organism
pulmonary	1081	1090	B-Cell
capillary	1091	1100	I-Cell
endothelial	1101	1112	I-Cell
cells	1113	1118	I-Cell
with	1119	1123	O
HAH	1124	1127	B-Drug_or_compound
-	1127	1128	I-Drug_or_compound
cortisol	1128	1136	I-Drug_or_compound
at	1137	1139	O
10	1140	1142	O
(	1142	1143	O
-	1143	1144	O
5	1144	1145	O
)	1145	1146	O
M	1147	1148	O
(	1149	1150	O
with	1150	1154	O
respect	1155	1162	O
to	1163	1165	O
cortisol	1166	1174	B-Drug_or_compound
)	1174	1175	O
suppressed	1176	1186	O
their	1187	1192	O
DNA	1193	1196	O
synthesis	1197	1206	O
by	1207	1209	O
50	1210	1212	O
%	1212	1213	O
and	1214	1217	O
inhibited	1218	1227	O
their	1228	1233	O
migration	1234	1243	O
into	1244	1248	O
wounded	1249	1256	O
areas	1257	1262	O
of	1263	1265	O
confluent	1266	1275	O
monolayers	1276	1286	O
.	1286	1287	O

HAH	1288	1291	B-Drug_or_compound
-	1291	1292	I-Drug_or_compound
cortisol	1292	1300	I-Drug_or_compound
at	1301	1303	O
10	1304	1306	O
(	1306	1307	O
-	1307	1308	O
4	1308	1309	O
)	1309	1310	O
M	1311	1312	O
(	1313	1314	O
with	1314	1318	O
respect	1319	1326	O
to	1327	1329	O
cortisol	1330	1338	B-Drug_or_compound
)	1338	1339	O
did	1340	1343	O
not	1344	1347	O
suppress	1348	1356	O
the	1357	1360	O
DNA	1361	1364	O
synthesis	1365	1374	O
of	1375	1377	O
Lewis	1378	1383	B-Cell
lung	1384	1388	I-Cell
carcinoma	1389	1398	I-Cell
cells	1399	1404	I-Cell
.	1404	1405	O

Daily	1406	1411	O
i	1412	1413	O
.	1413	1414	O
p	1414	1415	O
.	1415	1416	O
injections	1417	1427	O
of	1428	1430	O
HAH	1431	1434	B-Drug_or_compound
-	1434	1435	I-Drug_or_compound
cortisol	1435	1443	I-Drug_or_compound
into	1444	1448	O
mice	1449	1453	B-Organism
bearing	1454	1461	O
s	1462	1463	O
.	1463	1464	O
c	1464	1465	O
.	1465	1466	O
sponge	1467	1473	O
implants	1474	1482	O
retarded	1483	1491	O
vascularization	1492	1507	O
of	1508	1510	O
the	1511	1514	O
sponge	1515	1521	O
,	1521	1522	O
and	1523	1526	O
injections	1527	1537	O
directly	1538	1546	O
into	1547	1551	O
the	1552	1555	O
sponge	1556	1562	O
abolished	1563	1572	O
vascularization	1573	1588	O
for	1589	1592	O
as	1593	1595	O
long	1596	1600	O
as	1601	1603	O
the	1604	1607	O
injections	1608	1618	O
were	1619	1623	O
continued	1624	1633	O
.	1633	1634	O

Daily	1635	1640	O
i	1641	1642	O
.	1642	1643	O
v	1643	1644	O
.	1644	1645	O
injections	1646	1656	O
of	1657	1659	O
HAH	1660	1663	B-Drug_or_compound
-	1663	1664	I-Drug_or_compound
cortisol	1664	1672	I-Drug_or_compound
at	1673	1675	O
doses	1676	1681	O
causing	1682	1689	O
no	1690	1692	O
apparent	1693	1701	O
toxicity	1702	1710	O
retarded	1711	1719	O
the	1720	1723	O
growth	1724	1730	O
of	1731	1733	O
solid	1734	1739	O
s	1740	1741	O
.	1741	1742	O
c	1742	1743	O
.	1743	1744	O

Lewis	1745	1750	B-Pathological_formation
lung	1751	1755	I-Pathological_formation
carcinomas	1756	1766	I-Pathological_formation
in	1767	1769	O
mice	1770	1774	B-Organism
by	1775	1777	O
up	1778	1780	O
to	1781	1783	O
65	1784	1786	O
%	1786	1787	O
.	1787	1788	O

In	1789	1791	O
all	1792	1795	O
of	1796	1798	O
these	1799	1804	O
assays	1805	1811	O
,	1811	1812	O
equivalent	1813	1823	O
treatments	1824	1834	O
with	1835	1839	O
a	1840	1841	O
mixture	1842	1849	O
of	1850	1852	O
the	1853	1856	O
HAH	1857	1860	B-Drug_or_compound
plus	1861	1865	O
cortisol	1866	1874	B-Drug_or_compound
was	1875	1878	O
significantly	1879	1892	O
less	1893	1897	O
effective	1898	1907	O
.	1907	1908	O

The	1909	1912	O
antiproliferative	1913	1930	O
effect	1931	1937	O
of	1938	1940	O
HAH	1941	1944	B-Drug_or_compound
-	1944	1945	I-Drug_or_compound
cortisol	1945	1953	I-Drug_or_compound
on	1954	1956	O
endothelial	1957	1968	B-Cell
cells	1969	1974	I-Cell
appeared	1975	1983	O
independent	1984	1995	O
of	1996	1998	O
the	1999	2002	O
glucocorticoid	2003	2017	B-Drug_or_compound
activity	2018	2026	O
of	2027	2029	O
the	2030	2033	O
steroid	2034	2041	B-Drug_or_compound
since	2042	2047	O
HAH	2048	2051	B-Drug_or_compound
conjugated	2052	2062	O
to	2063	2065	O
5	2066	2067	B-Drug_or_compound
beta	2068	2072	I-Drug_or_compound
-	2072	2073	I-Drug_or_compound
pregnane	2073	2081	I-Drug_or_compound
-	2081	2082	I-Drug_or_compound
3	2082	2083	I-Drug_or_compound
alpha	2084	2089	I-Drug_or_compound
,	2089	2090	I-Drug_or_compound
17	2090	2092	I-Drug_or_compound
alpha	2093	2098	I-Drug_or_compound
,	2098	2099	I-Drug_or_compound
21	2099	2101	I-Drug_or_compound
-	2101	2102	I-Drug_or_compound
triol	2102	2107	I-Drug_or_compound
-	2107	2108	I-Drug_or_compound
20	2108	2110	I-Drug_or_compound
-	2110	2111	I-Drug_or_compound
one	2111	2114	I-Drug_or_compound
,	2114	2115	O
a	2116	2117	O
steroid	2118	2125	B-Drug_or_compound
lacking	2126	2133	O
glucocorticoid	2134	2148	B-Drug_or_compound
or	2149	2151	O
mineralocorticoid	2152	2169	B-Drug_or_compound
activity	2170	2178	O
,	2178	2179	O
was	2180	2183	O
even	2184	2188	O
more	2189	2193	O
effective	2194	2203	O
at	2204	2206	O
inhibiting	2207	2217	O
DNA	2218	2221	O
synthesis	2222	2231	O
by	2232	2234	O
murine	2235	2241	B-Organism
pulmonary	2242	2251	B-Cell
capillary	2252	2261	I-Cell
endothelial	2262	2273	I-Cell
cells	2274	2279	I-Cell
than	2280	2284	O
was	2285	2288	O
HAH	2289	2292	B-Drug_or_compound
-	2292	2293	I-Drug_or_compound
cortisol	2293	2301	I-Drug_or_compound
.	2301	2302	O

In	2303	2305	O
conclusion	2306	2316	O
,	2316	2317	O
HAH	2318	2321	B-Drug_or_compound
-	2321	2322	I-Drug_or_compound
cortisol	2322	2330	I-Drug_or_compound
represents	2331	2341	O
the	2342	2345	O
prototype	2346	2355	O
of	2356	2358	O
a	2359	2360	O
new	2361	2364	O
class	2365	2370	O
of	2371	2373	O
angiogenesis	2374	2386	O
inhibitors	2387	2397	O
for	2398	2401	O
the	2402	2405	O
treatment	2406	2415	O
of	2416	2418	O
cancer	2419	2425	B-Pathological_formation
and	2426	2429	O
other	2430	2435	O
angiogenic	2436	2446	O
diseases	2447	2455	O
.	2455	2456	O

